IP Library Granted Patent US 9,789,076
Granted Patent B2
US 9,789,076 · App. 14/614,201 · Granted Oct 17, 2017

Bolus dose of hydroxycitric acid with glycerol

Inventors: Dallas L. Clouatre (Seattle, WA); Daniel E. Clouatre (Seattle, WA); Brad J. Douglass (Seattle, WA)
Assignee: GLYKON TECHNOLOGIES GROUP, LLC
A61K31/194A61J1/1412A61K9/0053A61K9/0095A61K9/14A61K9/145A61K31/00A61K31/216A61K36/185A61K36/42A61K36/74A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,789,076
App. No.
14/614,201
Granted
Oct 17, 2017
Kind
B2
Abstract

A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.

Claims (6)

1. A method of delivering a pharmaceutical composition consisting essentially of:

orally administering a liquid sealed dosage of a hydroxycitrate salt in combination with glycerol and a coffee extract, wherein the hydroxycitrate salt is administered in amount of 3.0 g to 4.5 g±20%, and the glycerol is present in an amount in a range of from 1.0 g to 4.0 g±20%, and

wherein the liquid sealed dosage is prepared by mixing glycerol in water wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the water is present in an amount of about 3 to 1 parts by volume to create a solution;

dissolving hydroxycitrate salt in the solution wherein the hydroxycitrate salt is present in a concentration ranging from about 1.1 to 1.7 molar dosage.

2. The method in claim 1 , wherein the hydroxycitrate salt is a stable hydroxycitrate salt selected from a group consisting of sodium, potassium, potassium-magnesium or magnesium hydroxycitrate; double- or triple-metal salts based on the counter ions magnesium, potassium or sodium; or any workable combination thereof and the dosage is administered in a therapeutically effective amount sufficient to suppress appetite.

3. The method of claim 1 , wherein the hydroxycitrate salt is a potassium-magnesium salt of (−)-hydroxycitric acid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2022
From: GLYKON TECHNOLOGIES GROUP, LLC
To: NUTRITION RESEARCH GROUP, LIMITED
Reel/Frame 058559/0645 →
ASSIGNMENT AND QUITCLAIM AND ACTION BY CONSENT OF MEMBERS OF GLYKON TECHNOLOGIES GROUP LIMITED LIABILITY COMPANY Recorded Sep 19, 2016
From: DOUGLASS, BRAD J.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 040069/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: CLOUATRE, DALLAS L.; CLOUATRE, DANIEL E.; DOUGLASS, BRAD J.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 034993/0413 →
Continuity (2)
Provisional Application 62081161 · Nov 18, 2014
Related Publication 20160136117A1 · May 19, 2016